Bank of America Upgrades Bayer Aktiengesellschaft (OTCMKTS:BAYRY) to Neutral

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by equities researchers at Bank of America from an “underperform” rating to a “neutral” rating in a research report issued to clients and investors on Friday, Briefing.com reports.

Separately, The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Bayer Aktiengesellschaft Stock Up 4.3 %

Shares of BAYRY traded up $0.33 during midday trading on Friday, hitting $8.05. 427,841 shares of the company’s stock traded hands, compared to its average volume of 1,505,937. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $31.63 billion, a price-to-earnings ratio of -9.25 and a beta of 1.04. Bayer Aktiengesellschaft has a 1 year low of $6.82 and a 1 year high of $13.82. The firm’s fifty day moving average is $7.38 and its 200-day moving average is $7.43.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. The firm had revenue of $12 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. As a group, sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.37 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.